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Abstract
Asymptomatic pancreatic cysts are a common clinical problem but only a minority of these cases progress to cancer. Our aim was to
compare the accuracy to detect malignancy of the 2015 American Gastroenterological Association (AGA), the 2012 International
Consensus/Fukuoka (Fukuoka guidelines [FG]), and the 2010 American College of Radiology (ACR) guidelines.
We conducted a retrospective study at 3 referral centers for all patients who underwent resection for an asymptomatic pancreatic
cyst between January 2008 and December 2013. We compared the accuracy of 3 guidelines in predicting high-grade dysplasia
(HGD) or cancer in resected cysts. We performed logistic regression analyses to examine the association between cyst features and
risk of HGD or cancer.
A total of 269 patients met inclusion criteria. A total of 228 (84.8%) had a benign diagnosis or low-grade dysplasia on surgical
pathology, and 41 patients (15.2%) had either HGD (n=14) or invasive cancer (n=27). Of the 41 patients with HGD or cancer on
resection, only 3 patients would have met the AGA guideline’s indications for resection based on the preoperative cyst characteristics,
whereas 30/41 patients would havemet the FG criteria for resection and 22/41 patientsmet the ACR criteria. The sensitivity, speciﬁcity,
positive predictive value, negative predictive value of HGD, and/or cancer of the AGA guidelines were 7.3%, 88.2%, 10%, and 84.1%,
compared to 73.2%, 45.6%, 19.5%, and 90.4% for the FG and 53.7%, 61%, 19.8%, and 88% for the ACR guidelines. In multivariable
analysis, cyst size>3cm, compared to3cm, (odds ratio [OR]=2.08, 95%conﬁdence interval [CI]=1.11, 4.2) and each year increase
in age (OR=1.07, 95% CI=1.03, 1.11) were positively associated with risk of HGD or cancer on resection.
In patients with asymptomatic branch duct-intraductal papillary mucinous neoplasms or mucinous cystic neoplasms who
underwent resection, the prevalence rate of HGD or cancer was 15.2%. Using the 2015 AGA criteria for resection would havemissed
92.6% of patients with HGD or cancer. The more “inclusive” FG and ACR had a higher sensitivity for HGD or cancer but lower
speciﬁcity. Given the current deﬁciencies of these guidelines, it will be important to determine the acceptable rate of false-positives in
order to prevent a single true-positive.
Editor: Raffaele Pezzilli.
Study highlights.
What is current knowledge.
Asymptomatic pancreatic cysts are a common clinical problem but only a minority of these cases progress to cancer.
Current management guidelines vary in their threshold recommendations for resection of suspected mucinous cystic neoplasms (MCN) and branch-duct intraductal
papillary mucinous neoplasms (BD-IPMNs).
What is new here.
The stringent resection criteria of the AGA guidelines led to a high rate of missed cancers with lower sensitivity for detecting HGD and cancer compared to the 2012
Fukuoka and 2010 American College of Radiology guidelines.
Cyst size greater than 3cm and advanced age were signiﬁcant independent predictors of malignancy on resection.
No single guideline provided high sensitivity for detection of malignant cyst without also increasing the false-positive rate.
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Abbreviations: ACR = American College of Radiology, AGA = American Gastroenterological Association, BD = branch duct,
EUS = endoscopic ultrasound, FG = Fukuoka guidelines, HGD = high-grade dysplasia, IPMN = intraductal papillary mucinous
neoplasm, MCN =mucinous cystic neoplasm, MD =main duct, NPV = negative predictive value, OR = odds ratio, PD = pancreatic
duct, PPV = positive predictive value.
Keywords: cystic neoplasm, pancreatic cystic neoplasm, pancreatic cysts
1. Introduction
Asymptomatic pancreatic cysts are a common clinical problem
but only a minority of these cases progress to cancer. Mucinous
cysts, which include intraductal papillary mucinous neoplasm
(IPMN) and mucinous cystic neoplasms (MCNs), are considered
premalignant lesions with the potential to progress to cancer.
However, natural history studies and surgical series of IPMNs
estimate their rate of malignant transformation range from 6% to
40%.[1–4] A recent pooled analysis of 12 surgical series involving
over 600 patients with surgically resected MCNs found a 15%
rate of malignancy.[5–7] The major challenge in the surveillance of
asymptomatic IPMNs and MCNs is their slow rate of cancer
progression and the inability to distinguish those that progress.
Known and suspected risk factors for cyst malignancy include
size of cyst≥3cm, presence of a solid component or mural nodule
within the cyst, main-duct IPMN (MD-IPMN), and dilation of
the pancreatic duct (PD).[5] Based on these cyst features multiple
management guidelines have been proposed to reﬁne the
indications for surgical resection and improve our ability to
identify cysts at higher risk of malignant transformation. There
are currently 3 main guidelines for the management for
pancreatic cystic lesions: The 2012 International Consensus
Guideline, also known as the Fukuoka Guidelines (FG),[7] the
2015 American Gastroenterological Association (AGA) guide-
lines,[8] and the American College of Radiology (ACR).[9] The
latter 2 guidelines address only asymptomatic, incidentally
discovered pancreatic cysts whereas the 2012 FG guidelines also
include symptomatic patients in their treatment algorithm. The
AGA guidelines further exclude all MD-IPMN which are
addressed by the other guidelines. Even in the cohort of
asymptomatic patients with incidentally discovered cysts there
are signiﬁcant differences in the resection thresholds suggested by
these 3 guidelines. There is no study to date that has directly
compared the diagnostic accuracy of these disparate guidelines in
a low-risk population, namely those with incidentally discovered,
asymptomatic non-MD cysts. Our aim was to compare the
accuracy of the 2015 AGA guidelines, the 2012 FG, and the 2010
ACR guidelines to detect malignancy in cysts by retrospectively
applying these criteria to patients at our centers who have already
undergone surgical resection for an asymptomatic, incidentally
discovered pancreatic cyst and thus have ﬁnal pathology
available to afﬁrm the presence or absence of suspected high-
grade dysplasia (HGD) or invasive cancer.
2. Methods
2.1. Patient selection
We conducted a retrospective study at 3 academic referral centers
for patients who underwent surgical resection for an asymptom-
atic pancreatic cyst from January 2008 to December 2013. Only
patients with MCN and branch duct (BD)-IPMNs (conﬁrmed on
surgical pathology) were included in the study. MD-IPMNs
(deﬁned as cysts withMDdilation>1cm) were excluded, as there
is general agreement that these cysts should be resected in ﬁt
patients because of their higher risk of malignant transformation.
Because we excluded all cysts with an associated PDdilation of>1
cm some BD-IPMNs with secondary MD dilation were also
excluded so that our study cohort would exactly match the
population addressed by the AGA guidelines. The subjects were
identiﬁed from prospectively maintained pancreatic cyst data-
bases. The databases capture all patients who underwent surgical
resection for any type of pancreatic cystic neoplasm. Patients with
nonspeciﬁc abdominal painnot attributable to pancreatitiswith an
incidentally discovered cyst on imaging were included in our study
after individual chart review by the investigators. We excluded
patients with any preoperative symptoms of chronic pancreatitis,
unexplainedweight loss, jaundice, orﬁndings consistentwithMD-
IPMN. In total, 269 patients (center 1=119, center 2=106, and
center 3=44) met inclusion criteria (Fig. 1). The Institutional
Review Board of each center approved the study.
2.2. Predictors used in comparing guidelines
Based on the 2012 FG guidelines, in an asymptomatic patient
with an incidental pancreatic cyst, the presence of any one of the
Figure 1. Flowchart of patients from 3 centers with asymptomatic pancreatic
cysts after excluding patients with main-duct intraductal papillary mucinous
neoplasm (IPMN), symptomatic cysts, and solid pancreatic masses.
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following cyst features seen on imaging and conﬁrmed by
endoscopic ultrasound (EUS) were considered indications for
surgical resection: cyst size ≥3cm, presence of mural nodule or
solid component, dilation of the PD > 5mm but not meeting
criteria of MD-IPMN, or suspicious or positive cytology for
malignant cells (Tanaka 2012). The AGA guidelines recognize 3
“high risk features”: cyst size≥3cm,mural nodule, and dilation of
the PD >5mm. The AGA recommends EUS with ﬁne needle
aspiration (EUS-FNA) when at least 2 of these features are present
on cross-sectional imaging and proceed to surgical resection after
EUS if at least 2 of these “high risk” cyst features are conﬁrmed on
EUS or there is positive cytology on FNA. Last the ACRs
recommendation for surgical resection is based heavily on cyst size
alone with a cutoff size of >3cm for resection in surgically ﬁt
patients. We excluded all symptomatic patients or those with
obstructive jaundice as all 3 guidelines agree these patients should
beoffered surgical resection ifmedicallyﬁt.We then retrospectively
reviewed and applied each of the 3 different guideline criteria for
operative management to each patient’s preoperative imaging and
EUS-FNA data to determine whether they would have met the
respective guideline criteria for resection (Table 1).
2.3. Pathologic diagnosis
All pathologic diagnoses were based on the resected pancreatic
surgical specimen. Malignant cysts were deﬁned as IPMN with
HGD or pancreatic adenocarcinoma, mucinous cystadenocarci-
noma, and pancreatic neuroendocrine cystic tumors. Benign cysts
were deﬁned as IPMN or MCN with low grade or moderate
dysplasia, lymphoepithelial cyst, serous cyst, or other benign
cystic lesions.
2.4. Statistical analysis
The baseline characteristics of the study cohort were compared
by 2-tailed Student t test for continuous variables and chi-squared
tests for categorical variables. The performance characteristics of
the guidelines were evaluated by calculating the sensitivity,
speciﬁcity, positive predictive value (PPV), negative predictive
value (NPV), and accuracy of the 3 guidelines in predicting HGD
or invasive cancer. Fisher exact test was used in the univariate
analysis to identify predictors of HGD or cancer on resection. All
covariates with P-value <.2 in the univariate analysis are
included in the multivariable model. Multivariable logistic
regression analysis was used to calculate odds ratios (ORs)
and 95% conﬁdence intervals (CIs) to identify preoperative cyst
features that were associated with risk of HGD and/or cancer on




The baseline characteristics of the study cohort, overall, and by
surgical pathology classiﬁcation of benign versus malignant are
shown in Table 2. Of the 269 patients included, 228 (84.8%) had
a benign diagnosis or low-grade cystic neoplasm based on
surgical pathology (deﬁned as low grade or moderate grade
IPMN or MCN), and 41 patients (15.2%) were classiﬁed as
malignant as they were diagnosed as either HGD (n=14) or
invasive cancer (n=27) on surgical pathology. The majority of
patients were female (71.1%). Patients who had HGD or
cancer were signiﬁcantly older than those who had a benign or
Table 1
Major guideline recommendations for resection of asymptomatic mucinous cyst.
Guideline Criteria needed for resection
2012 International Consensus Guideline (FG) Cyst size >3cm in asymptomatic, surgically ﬁt patient OR Mural nodule on EUS OR Dilation of pancreatic duct >5mm OR
Suspicious or positive cytology for malignant cells
2015 AGA Guideline Two of following features present concurrently: -cyst size >3cm -dilated pancreatic duct -mural nodule conﬁrmed on EUS
OR Positive cytology on FNA
2010 ACR White Paper recommendations Cyst size >3cm OR positive cytology on FNA
ACR=American College of Radiology, AGA=American Gastroenterological Association, EUS= endoscopic ultrasound, FG= Fukuoka guidelines, FNA= ﬁne needle aspiration.
Table 2
Characteristics of the study cohort stratiﬁed by ﬁnal pathology.
Total (n=269) LGD/benign N=228 HGD/cancer N=41 P
∗
Male N, % 78 (28.9) 64 (28.0) 14 (34.1) .21
Age, mean (SD) 67.0 (12.4) 66.4 (±12.4) 74 (±11.0) <.01
Cyst >3cm N, % 110 (1) 89 (39) 21 (51) .07
PD dilation 5–9mm N, % 19 (7.1) 16 (7.0) 3 (7.3) .47
Mural nodule (either EUS or imaging) N, % 53 (19.7) 44 (19.3) 9 (21.9) .34
Average size of cyst, cm (SD) 2.85 (1.7) 2.96 (1.66) 2.84 (1.53) .31
EUS performed† N, % 204 (75.8) 168 (73.7) 36 (87.8) .02
Cytology/FNA positive or suspicious N, % 3 (1.1) 0 (0) 3 (7.3) <.01
Met AGA criteria for resection N, % 30 (11.2) 27 (11.8) 3 (7.3) .20
Met ACR criteria for resection N, % 110 (40.9) 89 (39.0) 21 (51) .07
Met Fukuoka criteria for resection N, % 153 (56.8) 123 (53.9) 30 (73.1) .01
ACR=American College of Radiology, AGA=American Gastroenterological Association, EUS= endoscopic ultrasound, FNA=ﬁne needle aspiration, HGD=high-grade dysplasia, LGD= low-grade dysplasia,
PD=pancreatic duct, SD= standard deviation.
∗
P-values are based on t tests for continuous variables or chi-squared tests for categorical variables.
† EUS was performed in 54/119 of patients at center 1 and in all patients at centers 2 and 3.
Bold numbers for signiﬁcant P values.
Xu et al. Medicine (2017) 96:35 www.md-journal.com
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low-grade cyst (74 vs 66.4 years, respectively, P< .01). The most
commonly seen “high risk” features in all patients were a cyst size
greater than 3cm (41%), presence of mural nodule (20%), and
PD dilation (7%). Among those patients with benign or low-
grade cysts, compared to those with HGD or invasive cancer,
39% versus 51% had a cyst size ≥3cm, 19.3% versus 21.9% had
a visible mural nodule on imaging, and 7% versus 7.3% had PD
dilation of 5 to 9mm; no statistically signiﬁcant differences were
observed. Of those who ultimately had a cyst with HGD or
adenocarcinoma on surgical resection, 73.1% would have met
the FG criteria for resection, 51% met the ACR criteria for
resection based on cyst size >3cm, and only 7.3% met the AGA
resection criteria.
There are some inherentdifferences in the clinical practices of the
3 centers represented in this study,most notably in the frequencyof
EUS used in the evaluation of pancreatic cysts (supplemental
Table 1, http://links.lww.com/MD/B851). In center 1, EUS was
selectively performed in only a subset of patients (the other centers
performed EUS in all patients). In center 1, EUS was performed
only in cases when imaging did not met FG criteria (3 additional
patients underwent EUS with FG criteria). Our study was not
powered to evaluate the added beneﬁt of EUS in this cohort.
However, in center 1, the additional yield of identifying a mural
nodule or cytologywithmalignancy in these caseswas seen in 13%
of cases (6 additional mural nodules and 1 positive cytology). For
those patients who did not undergo EUS at center 1 the AGA
guideline algorithm for the use of EUS were extrapolated from the
cross-sectional imaging features found in those patients. The AGA
guideline criteria for surgical resection are similar to the AGA
criteria for the use of EUS-FNA.
Despite the overall high percentage of patients who underwent
EUS in the entire cohort (75.8%), FNA was positive, deﬁned by
suspicious or frankly malignant cells, in only 3 patients. These
were all conﬁrmed on resection to be invasive cancer. There was
no false-positive cytology in our cohort.
3.2. Comparison of the diagnostic value of the 2015 AGA,
2012 international guidelines, and 2010 ACR
recommendations for cyst resection
Of the 41 patients with HGD or cancer on resection, only 3
patients met the AGA guideline’s indications for resection based
on having at least 2 high-risk cyst features preoperatively. In
contrast, 30 out of the 41 patients met the FG criteria for
resection and 22 out of 41 patients met the ACR recommendation
to undergo resection (Table 3). Hence, the “miss rate” for HGD
or cancer is 92.7% if the AGA guidelines for resection were
applied versus a “miss rate” of 48.8% and 26.8% using the ACR
and FG guidelines, respectively. Conversely, of the 228 patients
who ultimately had a benign diagnosis, “unnecessary” surgery
would have been recommended for a low grade or benign cystic
lesion in 11.8% of patients if the AGA guidelines were applied,
compared to 39% and 54% if the ACR and FG were used
(Table 2). The sensitivity, speciﬁcity, PPV, and NPV of the AGA
guidelines were 7.3%, 88.2%, 10%, and 84.1% compared to
73.2%, 45.6%, 19.4%, and 90.4% for the FG (Table 4). Using
the lone criteria of size>3cm the ACR guidelines had a sensitivity
of 53.7%, speciﬁcity of 61%, PPV 19.8%, and NPV 88% for
HGD or cancer on resection. The overall diagnostic accuracy of
the AGA guidelines was highest at 75.8% versus 49.8% for the
FG guidelines and 59.8% for the ACR guidelines.
3.3. Univariable and multivariable analysis for the
prediction of a malignant cyst
All covariates associated with HGD or cancer with a P value <.2
in the univariable analysis were included in the multivariable
model. In the multivariable analysis, older age (OR 1.07, 95%CI
1.03–1.11 for each 1 year increment, P< .01) and cyst size>3cm
compared to<=3cm (OR 2.08, 95%CI 1.02–4.27, P= .04) were
associated with an increased odds of HGD or cancer on resection.
4. Discussion
Incidentally discovered, asymptomatic pancreatic cysts from
imaging studies are a common clinical problemwith an estimated
prevalence of 3% to 15%. The incidence of these cysts increases
with age.[10] Although the majority of these asymptomatic cysts
pose no signiﬁcant clinical threat, a small proportion of IPMNs
and MCNs, can progress to cancer. Once invasive IPMN- or
MCN-based carcinoma is identiﬁed and there is locoregional
lymph node involvement, outcomes are similar to very poor
survival of stage-matched outcomes with pancreatic ductal
adenocarcinoma.[11] Prior to the publication of the 2015 AGA
Table 3
Proportion of patients with HGD or cancer by guideline criteria for resection.
Total
Cancer,















268 27 (10.1) 14 (5.2) 228 (85.1) 30 (11.2) 3 (1.1) 15 (57.5) 30 (11.2) 111 (41.4) 22 (7.8)
ACR=American College of Radiology, AGA=American Gastroenterological Association, CA= cancer antigen, FG= Fukuoka guidelines, HGD=high-grade dysplasia, LGD= low-grade dysplasia.
Table 4
Comparison of the performance characteristics of the major guidelines in predicting HGD or cancer on resection of asymptomatic
pancreatic cysts.
Sensitivity for HGD/CA (95%CI) Speciﬁcity for HGD/CA (95%CI) PPV (95% CI) NPV (95% CI) OR (95%CI) Accuracy
AGA criteria 7.3 (1.54–20) 88.2 (83–92) 10 (2.1–26.5) 84.1 (78.8–88.5) 0.59 (0.18–1.92) 75.8
Fukuoka criteria 73.2 (57.1–85.8) 45.6 (39–52.3) 19.4 (13.5–26.6) 90.4 (83.5–95.1) 2.3 (1.11–4.73) 49.8
ACR criteria 53.6 (37.4–69.3) 60.9 (54.3–67.3) 19.8 (12.9–28.5) 88 (81.9–92.6) 1.81 (0.93–3.5) 59.8
ACR=American College of Radiology, AGA=American Gastroenterological Association, CA= cancer antigen, CI= conﬁdence interval, HGD=high-grade dysplasia, NPV=negative predictive value, OR= odds
ratio, PPV=positive predictive value.
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guidelines the most widely used treatment algorithm in the
management of these asymptomatic pancreatic cysts was based
on the 2012 International Guidelines which recommended
resection for all MD-IPMNs, BD-IPMNs that are causing
symptoms (speciﬁcally jaundice, weight loss, or pancreatitis),
those with high-risk stigmata conﬁrmed on EUS such as mural
nodule, dilation of the PD, positive cytology for malignancy, and
size greater than 3cm in those who are surgically ﬁt.[7] Multiple
cohort studies have shown that the 2012 FG guidelines decrease
the number of patients who underwent unnecessary surgery for
low risk cysts, improve diagnostic accuracy, and have a higher
speciﬁcity compared to the previous guidelines.[12–15] However,
the relative predictive accuracy and importance of any individual
high-risk cyst feature and the cumulative risk conferred when
multiple features are present remains unclear. A large meta-
analysis involving 5788 patients found that cyst size >3cm was
the most highly predictive feature of malignancy with OR of 62,
compared to mural nodule with OR 9 andMD involvement, with
OR 7.[16] In line with this meta-analysis, the ACRs recommen-
dation for management of incidentally found, undifferentiated
pancreatic cysts on imaging suggests EUS for characterization,
cytology and then resection for nonserous cysts based solely on a
size cutoff of greater than 3cm.[9] In contrast to both of those
guidelines the 2015 AGA guidelines and the accompanying
technical review offered the most stringent criteria for the
resection of asymptomatic cysts to date. The AGA guidelines ﬁrst
require the presence of at least 2 high-risk features seen on cross-
sectional imaging for referral for EUS to further verify the
presence of these features. If EUS conﬁrms at least 2 high-risk
features are present, then the recommendation is made for
resection.
In our cohort of low risk patients with asymptomatic BD-
IPMN or MCNs who underwent resection, the overall rate of
HGD or cancer was 15.2%. This is within range of the reported
rate of malignancy in similar low-risk populations in the
literature.[16,17] Only 11% of all patients in our study would
have met the AGA criteria to undergo resection and 7.3% of
those who ultimately had HGD or cancer on resection met the
AGA surgical threshold. We found that using the 2015 AGA
guidelines improved the speciﬁcity of ﬁnding a malignant cyst on
resection to 88.2% compared to 45.6% and 61% using the 2012
FG and 2010 ACR guidelines. However, the sensitivity of the
AGA guidelines for detecting HGD or cancer is signiﬁcantly
lower at only 7.3% compared to 73.2% (2012 FG) and 53.7%
(2010 ACR). With the higher threshold for resection in the AGA
guidelines fewer patients (11.8%) would have undergone
“premature” surgery based on a benign or low-grade cyst on
resection.
The frequency of surgery for benign pathology in our cohort
may be due to 2 factors. First, our database range includes
patients from as early as 2008 prior to the publication of the ACR
or FG guidelines when less restrictive criteria could have been
used to prompt resection. Second, some of these patients were
referred to surgery based on a preoperative suspicion for MCN
from an elevated cyst ﬂuid carcinoembryonic antigen or amylase
level obtained during EUS-FNA. There is still some controversy
regarding the best management of MCN with the FG guidelines
recommending resection of all suspectedMCNs regardless of size
or presence of HGD.[7]
We found that a preoperative cyst size≥3cm and advanced age
were independently predictive of malignancy. This is similar to
the ﬁndings of the meta-analysis by Anand et al[16] which
identiﬁed a cyst size ≥3cm as the highest risk feature predictive of
malignant transformation. Other studies have suggested the
presence of mural nodule to be highly speciﬁc for malignancy but
this cyst feature was not found to be signiﬁcantly predictive of
cancer in our study.[14] One of the key limitations in the
development of accurate guidelines for the management of
pancreatic cysts has been that no single cyst feature has been
consistently found across the literature to be both highly sensitive
and speciﬁc formalignant potential. The ongoing investigation of
molecular markers may be helpful in further reﬁnement of our
treatment algorithms and prognostication for asymptomatic
cysts. Whole genome sequencing has identiﬁed some promising
markers of dysplastic and malignant cysts including gene
mutations in TP53, PIK3CA, and other mutations leading to
loss of PTEN expression.[18–20] One recently published study
looking at a small subgroup of patients with IPMNs who had
molecular testing in addition to the existing algorithms for risk-
stratifying mucinous cysts found the addition of molecular
testing increased the sensitivity for malignancy to 100%,
speciﬁcity of 90% in identifying high-grade or malignant
IPMNs.[21] Advances in molecular testing of pancreatic cysts
to both categorize and prognostic for discrimination and
accuracy requires larger scale, prospective validation but is a
promising addition to the imaging based risk-stratiﬁcation
algorithm we currently use.
One of the main limitations of our study is its retrospective
nature. This is a major limitation in almost all studies of the
natural history of these pancreatic cysts as the absolute rate of
malignant transformation is low and the time to malignancy
tends to be long. In addition all patients in our study had been
determined to need surgical resection for their asymptomatic
pancreatic cyst and thus may reﬂect an enriched population with
higher prevalence of concerning cyst features and thus a higher
rate of malignancy compared to a surveillance-only population.
However, we chose a surgical population for this study to ensure
that the histopathology of the cysts is conﬁrmed and the presence
of HGD or malignancy is unambiguous. An important additional
limitation is inherent to the binomial categorization of size
measurements for PD or cysts. For example, in a clinical setting a
9mm PD would be just as concerning as a 10mm, but in using
this criteria, this minimal difference shifts patients from one
group to the other.
In summary, we evaluated a large combined cohort of
asymptomatic patients with MCNs and applied 3 leading
guidelines to compare the relative accuracy of each guideline
in predicting advanced neoplasia on resection. The stringent
resection criteria of the AGA guidelines led to a high rate of
missed cancers and suffer from poor sensitivity compared to the
2012 FG and 2010 ACR guidelines. The 2012 FG guidelines had
the highest sensitivity in detecting neoplasia at 73.2% but this is
offset by low speciﬁcity of only 45.6%, thereby increasing
the number of unnecessary surgeries if these guidelines were
followed. There was no single cyst feature which was
independently predictive of malignancy. Given the grave
prognosis of pancreatic cancer and the poor relative performance
of all these guidelines, there is still an unresolved clinical dilemma
of determining the acceptable rate of false-positives in order to
prevent a single cancer. Based on our ﬁndings, we believe the
strict use of the AGA guidelines will lead to missing too many
cancers or high risk cyst lesions and therefore the routine use of
these guidelines in practice should not be adopted. However, our
study also shows the limitations associated with the earlier
guidelines and emphasizes the need for further research in this
area to identify better clinical predictors.
Xu et al. Medicine (2017) 96:35 www.md-journal.com
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